Cross-clade envelope glycoprotein 160-specific CD8+ cytotoxic T lymphocyte responses in early HIV type 1 clade B infection

AIDS Research and Human Retroviruses

Volumn 14, Issue 11, 1998, Pages 925-937

  Wilson, Susan E ^a   Pedersen, Shannon L ^a   Kunich, John C ^a   Wilkins, Victoria L ^a   Mann, Dean L ^b   Mazzara, Gail P ^c   Tartaglia, James ^d   Celum, Connie L ^e   Sheppard, Haynes W ^a  

^a VIRAL AND RICKETTSIAL DISEASE LABORATORY   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c Therion Biologics Corporation   (United States)

^d Virogenetics Corporation   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; POL PROTEIN; VIRUS ENVELOPE PROTEIN;

ALLELE; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; VIRUS ENVELOPE; VIRUS GENE;

EID: 0032551608     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.1998.14.925     Document Type: Article

References (65)

1. Haynes BF, Panteleo G, and Fauci AS: Toward an understanding of the correlates of protective immunity to HIV infection. Science 1996;271:324-328.
2. McMichael AJ and Walker BD: CTL epitopes: Implications for AIDS vaccines. AIDS 1994;8:S155-S173.
3. Autran B, Hadida F, and Haas G: Evolution and plasticity of CTL responses against HIV. Curr Opin Immunol 1996;8:546-553.
4. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowsky W, Farthing C, and Ho DD: Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency viras type 1 infection. J Virol 1994;68: 4650-4655.
5. Borrow P, Lewicki H, Hahn BH, Shaw GM, and Oldstone MBA: Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994;68:6103-6110.
6. Safrit JT, Andrews CA, Zhu T, Ho DD, and Koup RA: Characterization of human immunodeficiency virus type 1-specific cytotoxic T lymphocyte clones isolated during acute seroconversion: Recognition of autologous virus sequences within a conserved immunodominant epitope. J Exp Med 1994;179:463-472.
7. Borrow P, Lewicki H, Wei X, Horwitz MS, Peffer N, Meyers H, Nelson JA, Gairin JE, Hahn BH, Oldstone MBA, and Shaw GM: Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nature Med 1997;3:205-211.
8. Lamhamedi-Cherradi S, Culmann-Penciolelli B, Guy B, Duong Ly T, Goujard C, Guillet J-G, and Gomard E: Different patterns of HIV-1-specific cytotoxic T-lymphocyte activity after primary infection. AIDS 1995;9:421-426.
9. Lieberman J, Fabry JA, Mei Fong D, and Parkerson GR III: Recognition of a small number of diverse epitopes dominates the cytotoxic T lymphocyte response to HIV type 1 in an infected individual. AIDS Res Hum Retroviruses 1997;13:383-392.
10. Carmichael A, Jin X, Sissons P, and Borysiewicz L: Quantitative analysis of the human immunodeficiency virus type 1 (HlV-1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection. Differential responses to HIV-1 and Epstein-Barr virus in late disease. J Exp Med 1993;177:249-256.
11. Klein MR, van Baalen CA, Holwerda Am, Kerkhof Garde SR, Bende RJ, Keet IPM, Eeftinck-Schattenkerk JKM, Osterhaus ADME, Schuitemaker H, and Midema F: Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: A longitudinal analysis of rapid progressors and long-term asymptomatics. J Exp Med 1995; 181:1365-1372.
12. Rinaldo C, Huang X-L, Fan ZF, Ding M, Beltz L, Logar A, Panicali D, Mazzara G, Liebmann J, Cottrill M, and Gupta P: High levels of anti-human immunodeficiency type 1 (HIV-1) memory cytotoxic T lymphocyte activity and low viral load are associated with lack of disease in HIV-1 infected long-term nonprogressors. J Virol 1995;69:5838-5842.
13. Greenough TC, Brettler DB, Somasundaran M, Panicali DL, and Sullivan JL: Human immunodeficiency virus type 1-specific cytoto'xic T lymphocytes (CTL), viras load, and CD4 T cell loss: Evidence supporting the protective role for CTL in vivo. J Infect Dis 1997;176:118-125.
14. Goulder PJR, Phillips RE, Colbert RA, McAdam S, Ogg G, Nowak MA, Giangrande P, Luzzi G, Morgan B, Edwards A, McMichael AJ, and Rowland-Jones S: Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nature Med 1997;3:212-217.
15. McMichael AJ and Phillips RE: Escape of human immunodeficiency viras from immune control. Annu Rev Immunol 1997; 15:271-296.
16. Harrer T, Harrer E, Kalams SA, Elbeik T, Staprans SI, Feinberg MB, Cao Y, Ho DD, Yilma T, Caliendo AM, Johnson RP, Buchbinder SP, and Walker BD: Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection. AIDS Res Hum Retroviruses 1996;12:585-592.
17. Harrer T, Harrer E, Kalams SA, Barbosa P, Trocha A, Johnson RP, Elbeik T, Feinberg MB, Buchbinder SP, and Walker BD: Cytotoxic T lymphocytes in asymptomatic long-term nonprogressing HIV-1 infection. Breadth and specificity of the response, and relation to in vivo viral quasispecies in a person with prolonged infection and low viral load. J Immunol 1996;156:2616-2623.
18. Goulder PJR, Bunce M, Krausa P, McIntyre K, Crowley S, Morgan B, Edwards A, Giangrande P, Phillips RE, and McMichael AJ: Novel, cross-restricted, conserved, and immunodominant cytotoxic T lymphocyte epitopes in slow progressors in HIV type 1 infection. AIDS Res Hum Retroviruses 1996;12:1691-1698.
19. Langlade-Demoyen P, Ngo-Giang-Huong N, Ferchal F, and Oksenhendler E: Human immunodeficiency virus (HIV) Nef-specific cytotoxic T lymphocytes in noninfected heterosexual contact of HIV-infected patients. J Clin Invest 1994;93:1293-1297.
20. Rowland-Jones S, Sutton J, Ariyoshi K, Dong T, Gotch F, McAdam S, Whitby D, Sabally S, Gallimore A, Corrah T, Takiguchi M, Schultz A, McMichael A, and Whittle H: HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nature Med 1995;1:59-64.
21. Pinto LA, Sullivan J, Berzofsky JA, Clerici M, Kessler HA, Landay AL, and Shearer GM: ENV-specific cytotoxic T lymphocyte responses in HIV seronegative health care workers occupationally exposed to HIV-contaminated body fluids. J Clin Invest 1995;96: 867-876.
22. Cheynier R, Langlade-Demoyen P, Marescot M-R, Blanche S, Blondin G, Wain-Hobson S, Griscelli C, Vilmer E, and Plata F: Cytotoxic T lymphocyte responses in the peripheral blood of children born to human immunodeficiency virus-1 infected mothers. Eur J Immunol 1992;22:2211-2217.
23. Rowland-Jones S, Nixon DF, Aldhous MC, Gotch F, Ariyoshi K, Hallam N, Kroll JS, Froebel K, and McMichael A: HIV-speicifc cytotoxic T-cell activity in an HIV-exposed but uninfected infant. Lancet 1993;341:860-861.
24. Myers G, Korber B, Foley B, Jeang K-T, Mellors JW, and Wain-Hobson S (eds.): Human Retroviruses and AIDS Database 1996. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, New Mexico, 1996.
25. Chameau P, Borman AM, Quillent C, Guetard D, Cohen J, Reny G, Montagnier L, and Clavel F: Isolation and envelope sequence of a highly divergent HIV-1 isolate: Definition of a new HIV-1 group. Virology 1994;205:247-253.
26. Girard M, Barré-Sinoussi F, Van Der Ryst E, and Fultz P: An approach to vaccines against human immunodeficiency virus. AIDS Res Hum Retroviruses 1996;12:461-463.
27. Ada GL and McElrath MJ: HIV type 1 vaccine-induced cytotoxic T cell responses: Potential role in vaccine efficacy. AIDS Res Hum Retroviruses 1997;13:205-210.
28. McElrath MJ, Siliciano RF, and Weinhold KJ: HIV type 1 vaccine-induced cytotoxic T cell responses in phase I clinical trials: Detection, characterization, and quantitation. AIDS Res Hum Retroviruses 1997;13:211-216.
29. Ferrari G, Humphrey W, McElrath MJ, Excler J-L, Duliege A-M, Clements M-L, Corey LC, Bolognesi DP, and Weinhold KJ: Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Proc Natl Acad Sci USA 1997;94:1396-1401.
30. Cao H, Kanki P, Sankale J-L, Dieng-Sarr A, Mazzara GP, Kalams SA, Korber B, Mboup S, and Walker BD: Cytotoxic T-lymphocyte cross-reactivity among different human immunodeficiency virus type 1 clades: Implications for vaccine development. J Virol 1997;71:8615-8623.
31. Betts MR, Krowka J, Santamaria C, Balsamo K, Gao F, Mulundu G, Luo C, N'Gandu N, Shepphard H, Hahn BH, Allen S, and Frehlinger JA: Cross-clade human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte responses in HIV-infected Zambians. J Virol 1997;71:8908-8911.
32. Kalams SA, Johnson RP, Dynan MJ, Hartman KE, Harrer T, Harrer E, Trocha AK, Blattner WA, Buchbinder SP, and Walker BD: T cell receptor usage and fine specificity of human immunodeficiency virus 1-specific cytotoxic T lymphocyte clones: Analysis of quasispecies recognition reveals a dominant response directed against a minor in vivo variant. J Exp Med 1996;183:1669-1679.
33. Wilson CC, Kalams SA, Wilkes BM, Ruhl DJ, Gao F, Hahn BH, Hanson IC, Luzuriaga K, Wolinsky S, Koup R, Buchbinder SP, Johnson RP, and Walker BD: Overlapping epitopes in human immunodeficiency virus type 1 gp120 presented by HLA A, B, and C molecules: Effects of viral variation on cytotoxic T-lymphocyte recognition. J Virol 1997;71:1256-1264.
34. Tomiyama H, Miwa K, Shiga H, Ikeda Moore Y, Oka S, Iwamato A, Kaneko Y, and Takiguchi M: Evidence of presentation of multiple HIV-1 cytotoxic T lymphocyte epitopes by HLA-B*3501 molecules that are associated with the accelerated progression of AIDS. J Immunol 1997;158:5026-5034.
35. Fernandez MH, Fidler SJ, Pitman RJ, Weber JN, and Rees ADM: CD4+ T-cell recognition of diverse clade B HIV-1 isolates. AIDS 1997;11:281-288.
36. Korber B, Hoellscher M, McCutchan F, Williamson C, von Sonnenburg F, Mullins J, Pletschette M, Weber J, van der Groen G, and Osmamov S: HIV-1 subtypes: Implications for epidemiology, pathogenicity, vaccines, and diagnostics. Workshop report from the European Commission (DG XII, INCO-DC) and the Joint United Nations Programme on HIV/AIDS. AIDS 1997;11:17-36.
37. Mulder J, McKinney N, Chirstopherson C, Sninsky J, Greenfield L, and Kwok S: Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: Application to acute retroviral infection. J Clin Microbiol 1994;32: 292-300.
38. Delwart EL, Shpaer EG, Louwagie J, McCutchan FE, Grez M, Rübsamen-Waigmann H, and Mullins JI: Genetic relationships determined by a DNA heteroduplex mobility assay: Analysis of HIV-1 env genes. Science 1993;262:1257-1261.
39. Gao F, Morrison SG, Robertson DL, Thornton CL, Craig S, Kartsson G, Sodroski J, Morgado M, Galvao-Castro B, von Bliesen H, et al.: Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. The WHO and NIAID Networks for HIV Isolation and Characterization. J Virol 1996;70:1651-1667.
40. Gao F, Robertson DL, Morrison SG, Hui H, Craig S, Decker J, Fultz PN, Girard M, Shaw GM, Hahn BH, and Sharp PM: The heterosexual human immunodeficiency virus type 1 epidemic in Thailand is caused by an intersubtype (A/E) recombinant of African origin. J Virol 1996;70:7013-7029.
41. Perkus ME, Limbach K, and Paoletti E: Cloning and expression of foreign genes in vaccinia virus, using a host range selection system. J Virol 1989;63:3829-3836.
42. Goebel SJ, Johnson GP, Perkus ME, Davis SW, Winslow JP, and Paoletti E: The complete DNA sequence of vaccinia virus. Virology 1990;179:247-266.
43. Smith K, Stallard V, Roos J, Hart C, Cormier N, Cohen L, Roberts B, and Payne L: Host range selection of vaccinia recombinants containing insertions of foreign genes into non-coding sequences. Vaccine 1993;11:43-53.
44. Ferrari G, King K, Rathbun K, Place CA, Packard MV, Bartlett JA, Bolognesi DP, and Weinhold KJ: IL-7 enhancement of antigen-driven activation/expression of HIV-1-specific cytotoxic T lymphocyte precursors (CTLp). Clin Exp Immunol 1995;101: 239-248.
45. Leitner T: Genetic subtypes of HIV-1. In: The Human Retroviruses and AIDS 1996 Compendium (Myers G, Korber B, Foley B, Jeang K-T, Mellors JW, and Wain-Hobson S, eds.), Part III. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, New Mexico, 1996.
46. Safit JT, Lee AY, Andrews CA, and Koup RA: A region of the third variable loop of HIV-1 gp120 is recognized by HLA-B7-restricted CTLs from two acute seroconversion patients. J Immunol 1994;153:3822-3830.
47. Korber B, Walker B, Brander C, Koup R, Moore J, Haynes BF, D'Souza PM, and Myers G (eds.): HlV-1 CTL epitopes In: HIV Molecular Immunology Database, Part I. Los Alamos National Laboratory, Los Alamos, New Mexico, 1996, pp. 1-156.
48. MN. J Infect Dis 1994;169:274-280.
49. Sidney J, Southwood S, del Guercio M-F, Grey HM, Chesnut RW, Kubo RT, and Sette A: Specificity and degeneracy in peptide binding to HLA-B7-like class I molecules. J Immunol 1996;157:3480-3490.
50. Sidney J, Grey HM, Kubo RT, and Sette A: Practical, biochemical and evolutionary implications of the discovery of HLA class I supermotifs. Immunol Today 1997;17:261-266.
51. Brander C and Walker BD: The HLA-class I restricted CTL response in HIV-1 infection: Identification of optimal epitopes. In: HIV Molecular Immunology Database 1996 (Korber BTM, Walker BD, Brander C, Koup R, Moore JP, Haynes BF, D'Souza PM, and Myers G, eds.), Part IV. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, New Mexico, 1996, pp. 50-60.
52. Niedermann GS, Butz S, Ihleinfeldt HG, Grimm R, Lucchiari M, Hoschutzky H, Jung G, Maier B, and Eichman K: Contribution of proteasome-mediated proteolysis to the hierarchy of epitopes presented by major histocompatibility class I molecules. Immunity 1995;2:289-299.
53. Hammond SA, Johnson RP, Kalams SA, Walker BD, Takiguchi M, Safrit JT, Koup RA, and Siliciano RF: An epitope-selective, transporter associated with antigen presentation (TAP)-1/2-independent pathway and a more geneal TAP-1/2-dependent antigen-processing pathway allow recognition of the HIV envelope glycoprotein by CD8+ CTL. J Immunol 1995;154:6140-6156.
54. Neisig A, Wubbolts R, Zang X, Melief C, and Neefjes J: Allele-specific differences in the interaction of MHC class I molecules with transporters associated with antigen processing. J Immunol 1996;156:3196-3206.
55. Chen W, Khilko S, Fecondo J, Margulies DH, and McCluskey J: Determinant selection of major histocompatibility complex class I-restricted antigenic peptides is explained by class I-peptide affinity and is strongly influenced by non-dominant anchor residues. J Exp Med 1994;180:1471-1483.
56. Pogue RR, Eron J, Frehlinger JA, and Matsui M: Amino-terminal alteration of the HLA-A *0201-restricted human immunodeficiency virus Pol peptide increases complex stability and immunogenicity. Proc Natl Acad Sci USA 1995;92:8166-8170.
57. Pantaleo G, Demarest JF, Schacker T, Vaccarezza M, Cohen OJ, Daucher M, Graziosi C, Schnittman SS, Quinn TC, Shaw GM, et al.: The quantitative nature of the primary immune response to HIV infection is a prognostic marker of disease progression independent of the initial level of plasma viremia. Proc Natl Acad Sci USA 1997;94:254-258.
58. Nelson GW, Kaslow R, and Mann DL: Frequency of HLA allele-specific peptide motifs in HIV-1 proteins correlates with the allele's association with relative rates of disease progression after HIV-1 infection. Proc Natl Acad Sci USA 1997;94: 9802-9807.
59. Delwart EL, Sheppard HW, Walker BD, Goudsmit J, and Mullins JI: Human immunodeficiency virus type 1 evolution in vivo tracked by DNA heteroduplex mobility assays. J Virol 1994;68:6672-6683.
60. Delwart EL, Pan H, Sheppard HW, Wolpert D, Neumann AU, Korber B, and Mullins JI: Slower evolution of human immunodeficiency virus type 1 quasispecies during progression to AIDS. J Virol 1997;71:7498-7508.
61. Lukashov VV, Kuiken CL, and Goudsmit J: Intrahost human immunodeficiency virus type 1 evolution is related to length of the immunocompetent period. J Virol 1995;69:6911-6916.
62. Wolinsky SM, Korber BTM, Neumann AU, Daniels M, Kunstman KJ, Whetsell AJ, Furtado MR, Cao Y, Ho DD, Safrit JT, and Koup RA: Adaptive evolution of human immunodeficieney virus-type 1 during the natural course of infection. Science 1996;272:537-542.
63. Goulder PJR, Sewell AK, Lalloo DG, Price DA, Whelan JA, Evans J, Taylor GP, Luzzi G, Giangrande P, Phillips RE, and McMichael AJ: Patterns of immunodominance in HIV-1-specific cytotoxic T lymphocyte responses in two human histocompatibility leukocyte antigens (HLA)-identical siblings with HLA-A*0201 are influenced by epitope mutation. J Exp Med 1997;185:1423-1433.
64. Zhu T, Mo H, Wang H, Nam DS, Cao Y, Koup RA, and Ho DD: Genotypic and phenotypic characterization of HIV-1 in patients with primary infection. Science 1993;261:1179-1181.
65. Haynes BF: HIV vaccines: Where we are and where we are going? Lancet 1996;348:933-937.